Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beigene ADS Representing Ord Shs ONC

Healthcare Biotechnology
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the... see more

Recent & Breaking News (NDAQ:ONC)

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Business Wire 2 days ago

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

Business Wire 12 days ago

BeiGene to Change Nasdaq Ticker Symbol to "ONC" on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

Business Wire December 23, 2024

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Business Wire December 12, 2024

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Business Wire December 9, 2024

BeiGene and CLL Society Partner to Advance Test Before Treat(TM) Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

Business Wire December 4, 2024

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

Business Wire December 2, 2024

European Commission Approves BeiGene's TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

Business Wire November 27, 2024

BeiGene to Present at Upcoming Investor Conferences

Business Wire November 26, 2024

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

PR Newswire November 19, 2024

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Business Wire November 19, 2024

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

Business Wire November 14, 2024

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

Business Wire November 12, 2024

BeiGene to Present at the Jefferies London Healthcare Conference

Business Wire November 6, 2024

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Business Wire November 5, 2024

BeiGene Mourns Death of Beloved Board Member Donald Glazer

Business Wire October 28, 2024

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

Business Wire October 21, 2024

BeiGene Highlights Waldenström's Macroglobulinemia Innovation at IWWM 2024

Business Wire October 16, 2024

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

Business Wire September 26, 2024

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

Business Wire September 26, 2024